Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
ACCESS Tests Effect of Eliminating Co-pay on CV Outcomes
March 1st 2023Braden Manns, MD, MSc, a nephrologist and health economics researcher at the University of Calgary in Canada, will present the results of a randomized trial evaluating the impact of removing co-payments for drugs that treat chronic conditions on cardiovascular outcomes during the American College of Cardiology Scientific Sessions in New Orleans, Louisiana, on Sunday, March 5.
Read More
On Rare Disease Day, PKD Foundation, IQVIA Highlight Patient Registry Gathering Quality-of-Life Data
February 28th 2023The Polycystic Kidney Disease Foundation and IQVIA are partners in the development of the ADPKD Registry, which is tracking longitudinal quality-of-life information from patients across North America.
Read More
Additional Results From POLARIX Study Show Improved PFS With No Reduction in HRQOL
January 29th 2023New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.
Read More
PolaR-ICE Effective as Second-line Treatment in DLBCL, Bridge to Autologous Stem Cell Transplant
January 28th 2023Results presented during the 64th American Society of Hematology Annual Meeting and Exposition could offer an effective option for those with relapsed or refractory DLBCL, even as chimeric antigen receptor T-cell therapy becomes standard of care for many patients.
Read More
Tucatinib Plus Trastuzumab Approved for RAS Wild-type, HER2+ Unresectable or Metastatic CRC
January 19th 2023The combination of tucatinib and trastuzumab received accelerated approval from the FDA to treat adults with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer (mCRC) that advances after treatment with specific types of chemotherapy.
Read More
From Lymphomas to Myeloma, Bispecific Antibodies Make a Big Splash at ASH
January 14th 2023At the 2022 annual meeting of the American Society of Hematology (ASH), customized cancer immunotherapy treatments now share the limelight with bispecific antibodies, which made news across disease states from large B-cell lymphoma to follicular lymphoma to multiple myeloma; as their name suggests, these treatments aim at 2 targets, increasing their potency against cancer.
Read More